Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 1/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1823706 | 0.78 | SLC6A1 (0.34) | SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL19004167 | 0.78 | SLC6A1 (0.34) | SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL13697534 | 0.68 | SLC6A1 (0.34) | SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL15319268 | 0.68 | SLC6A1 (0.54) | SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL11217697 | 0.67 | SLC6A1 (0.35) | SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL12389986 | 0.67 | SLC6A1 (0.35) | SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL9823369 | 0.67 | SLC6A1 (0.33) | SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL9823374 | 0.67 | SLC6A1 (0.33) | SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL11392518 | 0.64 | PLA2G1B (0.36) | SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL2038757 | 0.64 | L3MBTL1 (0.33) | SLC6A1SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754207-B2 | Process for the preparation of rapamycin derivatives | CADILA HEALTHCARE LIMITED (IN) | 2014-06-17 | — | — | US | disclosed |
| US-20120202988-A1 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202988-A1 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | RICTOR, MTOR, RPTOR | SLC6A1 3378/4885SLC6A12 4853/4885SLC6A11 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.